IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: To be Assigned

Examiner: To be Assigned

Attorney's Docket No: 13265-1247 C6

In re application of:

John J. NESTOR, Jr., et al.

Application No. To be Assigned (based on 09/903,221 – filed July 10, 2001)

Filed: Herewith

For: 2-(2-AMINO-1, 6-DIHYDRO-6-

OXO-PURIN-9-YL) METHOXY-1,3-PROPANEDIOL DERIVATIVE

EXPRESS MAIL LABEL NO. EV 346 728 181 US

Date Mailed: JUNE 24, 2003

INFORMATION DISCLOSURE STATEMENT

Mail Stop Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir

Applicants wish to bring to the attention of the Patent Office the references listed on the attached form PTO-1449 and request that they be considered by the Examiner. Each of the references listed on the attached form PTO-1449, was previously cited by or submitted to the PTO in prior Application Serial No. <u>09/903,221</u>, filed <u>July 10, 2001</u>, therefore copies are not enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3), therefore no fee is due. The Commissioner is authorized to charge any fees which may be required under 37 CFR §1.16 or §1.17, to Deposit Account No. <u>08-1641</u>, referencing Attorney's Docket No. <u>13265-1247 C6</u>.

Respectfully submitted,

Date: June 24, 2003

Herwig von Morzé (Reg. No. 29,484)

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

| | SUPPLE | MENTAL FO | orm PTO-1449 | Attorney's Docket No. 13265-12 | Attorney's Docket No. 13265-1247 C6 Application Serial No. To be Assigned | | | | |
|----------------------|-------------|---|---------------------------|---|--|--|--|--|--|
| INFO | RMATIC | ON DISCLOS | SURE STATEMENT | Applicant(s) John | J. NESTOR, J | • | | | |
| | (use se | veral sheets | if necessary) | Filing Date: June 24, 2003 Group Art U | | oup Art Unit: | it: To be Assigned | | |
| A POST | 100000 | | A fill of the fill of the | U.S. PATENT DOCUMENTS | and the second | | | | |
| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date (if appropriate) | | |
| | 1.* | 10/1982 | 4,355,032 | Verheyden, et al. | 424 | 253 | | | |
| | 2.* | 8/1991 | 5,043,339 | Beauchamp, Lilia M. | 514 | 274 | | | |
| • | 3.* | 7/2000 | 6,083,953 | Nestor, et al. | 544 | 276 | | | |
| | | entition of the second of the | DE THE FO | REIGN PATENT DOCUMENTS | ing and the second | | | | |
| Examiner Initials | Ref. | Date | Document No. | Country | Class | Subclass | Translation | | |
| | No. | | _ | | <u> </u> | _ • | YES | NO | |
| | 4.* | 6/1978 | 1 523 865 | Great Britain | | | | | |
| | 5.* | 3/1983 | 2 104 070 | Great Britain | | | | | |
| | 6.* | 1/1984 | 2 122 618 | Great Britain | | <u> </u> | | | |
| | 7.* | 6/1990 | 8829571 | Great Britain (application) | | 7 | | | |
| | 8.* | 10/1985 | 0 158 847 | Europe | | 7 | | | |
| | 9.* | 7/1986 | 0 187 297 | Europe | | | | | |
| | 10.* | 12/1987 | 0 249 248 | Europe | | | | | |
| , - | 11.* | 3/1989 | 0 308 065 | Europe | | | <u> </u> | 1 | |
| | 12.* | 6/1990 | 0 375 329 | Europe | | | | 1 | |
| | 13.* | 12/1994 | WO 94/29311 | PCT | · | † | | | |
| | | | (including | OTHER DOCUMENTS author, title, date, pertinent pages, etc | C.) | | | | |
| Examiner Initials | Ref. | Title | | | | | | | |
| | No. 14.* | L.M. Beauchamp, et al., "Amino Acid Ester Prodrugs of Acyclovir"., <i>Antiviral Chemistry & Chemotherapy</i> – 3(3):157-164 (1992) | | | | | | | |
| | 15.* | Bodanszky, "Principles of Peptide Synthesis, 2 nd edition (Springer-Verlag) pages 9-11 | | | | | | | |
| | 16.* | L. Colla, et al., "Synthesis and Antiviral Activity of Water-Soluble Esters of Acyclovir", J. Med. Chem. – 26:602-604 (1983) | | | | | | | |
| | 17.* | Crumpacker, New England Journal of Medicine 335, 10, 721-727 (1996) | | | | | | | |
| | 18.* | E. Jensen, et al., "Synthesis, Enzymatic Hydrolysis and Physico-Chemical Properties", Acta Pharm. Nord 3(4):243-247 (1991) | | | | | | | |
| | 19.* | J.C. Martin, et al., "Synthesis and Antiviral Activity of Various Esters", J. Pharm. Sci 76(2):180-184 (1987) | | | | | | | |
| | 20.* | P.C. Maudgal, et al., "Topical Treatment of Experimental Herpes Simplex Keratouveitis", <i>Arch. Ophthalmol.</i> – 102:140-142 (1984) | | | | | | | |
| | 21.* | Merck Index, 13th ed., page 29 | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | · | | | , | | | | | |
| | 1 | 1 | | | | | · · · · · · · · · · · · · · · · · · · | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with n xt communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).